Apricus inks Nitromist rights deal with NovaDel
The FDA-approved NitroMist is a nitrate vasodilator indicated for acute relief of an attack or acute prophylaxis of angina pectoris (chest pain) due to coronary artery disease. Developed
Telix Pharmaceuticals has officially opened a radiopharmaceutical research, manufacturing, and treatment facility in Melbourne, Australia, to expedite the delivery of new treatments for cancer.